EE276 Economic Evaluation of Trifluridine and Tipiracil Hydrochloride in the Treatment of Metastatic Gastric Cancer in the Brazilian Private Health Care Sector

Abstract

The Brazilian Private Health Care Sector has first-line and second-line metastatic gastric cancer (mGC) treatment options using traditional chemotherapy and targeted therapy. Recently, trifluridine and tipiracil hydrochloride (FTD/TPI) was approved in the third-line treatment and is the only treatment option to this subgroup of patients. Our objective was to evaluate the cost-effectiveness of FTD/TPI in mGC patients, including gastroesophageal junction adenocarcinoma, who have received at least two prior therapies for metastatic disease and are eligible for third-line treatment, from the perspective of private health care sector in Brazil.